FAIRFIELD, Conn.--(BUSINESS WIRE)--
Calmare
Therapeutics Incorporated (OTCQB: CTTC) (CTI), the Calmare®
pain mitigation company, discusses settlement with GEO-MC, Ltd. The
disagreement dates back to the third quarter of 2014.
"Our flagship medical device, the Calmare® Pain Therapy
Device, improves the quality of life of chronic neuropathic pain
patients' like no other modality on the market today," said Calmare
Therapeutics President and CEO Conrad Mir. "Legal matters and similar
distractions take away from the greater good Calmare Pain Mitigation
Therapy™ can bring. We need to turn the page on this matter and get back
to what Calmare Therapeutics does best – give chronic pain patients
their life back. They deserve our unconditional commitment to this
resolution if not more."
Calmare Pain Mitigation Therapy™
Calmare Pain Mitigation Therapy™ (PMT) has successfully improved the
quality of life of chronic neuropathic pain patients across the globe
without need of invasive treatments or prescription drugs. Calmare PMT
offers comprehensive prolonged pain
mitigation for 3 to 4 months. And, in those patients that are true
responders patients may have full pain elimination that may last up to a
year or more.
About the Company
Calmare Therapeutics Incorporated, the Calmare Pain Mitigation Therapy™
company, researches, develops and commercializes its flagship medical
device – the non-invasive and non-addictive Calmare® Pain
Therapy Device. The Company holds the U.S. Food & Drug Administration
510k clearance on its Device, which grants it the exclusive right to
sell, market, research and develop the medical device. Calmare Devices
are commercially sold to medical practices throughout the world. They
are also found in U.S. military hospitals, clinics and installations via
CTI's General
Services Administration (GSA) military contract (V797P-4300B).
Forward-Looking Statement
Certain statements contained in this press release are
forward-looking statements that involve risks and uncertainties. The
statements contained herein that are not purely historical are forward
looking statements within the meaning of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Forward-looking statements deal with the Company's
current plans, intentions, beliefs and expectations and statements of
future economic performance. Forward-looking statements involve known
and unknown risks and uncertainties that may cause the Company's actual
results in future periods to differ materially from what is currently
anticipated. Factors that could cause or contribute to such differences
include those discussed from time to time in reports filed by the
Company with the Securities and Exchange Commission. The Company cannot
guarantee its future results, levels of activity, performance or
achievements.
www.calmaretherapeutics.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160204005975/en/
